Oragenics, Inc. (NYSE:OGEN - Get Free Report)'s stock price fell 4.6% on Thursday . The stock traded as low as $3.34 and last traded at $3.53. 209,517 shares were traded during trading, an increase of 105% from the average session volume of 102,268 shares. The stock had previously closed at $3.70.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen began coverage on shares of Oragenics in a report on Thursday, May 15th. They set a "sell" rating on the stock.
Get Our Latest Research Report on OGEN
Oragenics Stock Up 1.2%
The stock has a 50 day simple moving average of $5.35 and a 200 day simple moving average of $7.83. The company has a market cap of $3.10 million, a price-to-earnings ratio of -0.61 and a beta of 0.94.
About Oragenics
(
Get Free Report)
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Stories
Before you consider Oragenics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oragenics wasn't on the list.
While Oragenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
